A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss

Simply Wall St.03-11

Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618256249?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-11 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618256249","market":"hk","top_or_hot":-1,"title":"A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss","media":"Simply Wall St.","content":"<div>\n<p>Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results","article_id":"2618256249","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/a-look-at-nuvation-bio-nuvb-valuation-after-its-2025-results","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618256249","pubTimestamp":1773235421,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone tracking the stock.\nSee our latest analysis for Nuvation Bio.\nThe latest earnings update and shelf registration come after a mixed share price run, with a recent 7 day share price return of 7.57% but a 90 day share price return decline of 40.18%. Despite that weaker near term momentum, the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc."},"translate_title":"Nuvation Bio(NUVB)2025年业绩显示收入增长和净亏损收窄后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1.5},"content_text":"Nuvation Bio (NUVB) just paired its latest earnings report with a new shelf registration filing, putting both its recent revenue profile and future capital raising options in sharper focus for anyone tracking the stock. See our latest analysis for Nuvation Bio. The latest earnings update and shelf registration come after a mixed share price run, with a recent 7 day share price return of 7.57% but a 90 day share price return decline of 40.18%. Despite that weaker near term momentum, the 1 year total shareholder return of 104.80% and 3 year total shareholder return of 182.53% point to a much stronger longer term picture than the current US$4.69 share price alone might suggest. If this mix of clinical progress, financing options, and volatility has your attention, it could be a good moment to widen your watchlist and look at 32 healthcare AI stocks as potential peers in the broader biotech and health tech space. So with revenue at US$62.9 million, a full year net loss of US$204.6 million, and a share price sitting well below the average analyst target, is Nuvation Bio being undervalued today, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 58.8% Undervalued According to the most followed narrative from Vestra, Nuvation Bio's fair value of $11.38 sits well above the last close at $4.69. This puts a spotlight on how earnings quality, revenue potential, and cash runway fit together.  Nuvation Bio (NUVB) is navigating a high-stakes transition into a commercial-stage oncology firm, with its stock trading at $4.74 as of the March 4, 2026, afternoon session. The shares saw a notable 8.60% recovery today, partially reclaiming ground after a staggering 25.34% drop on March 3rd following its latest financial disclosures.  Read the complete narrative. Read the complete narrative. Want to understand why a company with a recent annual net loss and early commercial traction still lands on a double digit fair value? The Vestra narrative leans heavily on fast scaling revenue, an oncology focused product already generating sales, and a margin profile that is expected to look very different from the current results. Curious which growth and profitability assumptions have to line up to bridge the gap between $4.69 and $11.38? The full story is in how those moving parts are modeled together. Result: Fair Value of $11.38 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on execution, with any setback in IBTROZI uptake or disappointing data from the safusidenib Phase 3 SIGMA trial likely to quickly undermine the current valuation story. Find out about the key risks to this Nuvation Bio narrative. Another View: Rich Multiples Signal a Different Story The Vestra fair value of $11.38 leans on future revenue, but today Nuvation Bio trades on a P/S ratio of 25.6x. That is far above the US pharmaceuticals average of 4x, the peer average of 12.1x, and even the 11.8x fair ratio our model suggests the market could move toward. For you, that gap raises a simple question: is this an opportunity, or is execution risk already high at this price? See what the numbers say about this price in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown. NYSE:NUVB P/S Ratio as at Mar 2026Next Steps With mixed signals on value and risk, does this story feel balanced or skewed to you? Act while the details are fresh and weigh both sides through 2 key rewards and 2 important warning signs. Looking for more investment ideas? If you are weighing what to do next after reading about Nuvation Bio, do not stop here. Broaden your opportunity set and let the data do more of the heavy lifting for you.  Target potential mispricings by scanning 48 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength. Prioritise resilience by reviewing 68 resilient stocks with low risk scores that screen for companies with lower risk scores so sharp surprises are less likely to catch you off guard. Get ahead of the crowd by combing through our screener containing 23 high quality undiscovered gems before they land on everyone else's radar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618256249","isCrawlerRequest":true}